CA3248916A1 - Pharmaceutical Composition of Antiplatelet Drugs and Their Use - Google Patents
Pharmaceutical Composition of Antiplatelet Drugs and Their UseInfo
- Publication number
- CA3248916A1 CA3248916A1 CA3248916A CA3248916A CA3248916A1 CA 3248916 A1 CA3248916 A1 CA 3248916A1 CA 3248916 A CA3248916 A CA 3248916A CA 3248916 A CA3248916 A CA 3248916A CA 3248916 A1 CA3248916 A1 CA 3248916A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- alkyl
- composition according
- heteroalkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210107273.0 | 2022-01-28 | ||
| CN202210107273 | 2022-01-28 | ||
| PCT/IB2023/050766 WO2023144782A1 (zh) | 2022-01-28 | 2023-01-30 | 抗血小板药物的药物组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248916A1 true CA3248916A1 (en) | 2025-01-17 |
Family
ID=87470993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3248916A Pending CA3248916A1 (en) | 2022-01-28 | 2023-01-30 | Pharmaceutical Composition of Antiplatelet Drugs and Their Use |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250152571A1 (enExample) |
| EP (1) | EP4470539A4 (enExample) |
| JP (1) | JP2025508331A (enExample) |
| KR (1) | KR20240142492A (enExample) |
| CN (1) | CN118613262A (enExample) |
| AU (1) | AU2023211946A1 (enExample) |
| CA (1) | CA3248916A1 (enExample) |
| IL (1) | IL314332A (enExample) |
| TW (1) | TW202339745A (enExample) |
| WO (1) | WO2023144782A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025108300A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用 |
| WO2025108307A1 (zh) * | 2023-11-24 | 2025-05-30 | 上海柯君医药科技有限公司 | 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用 |
| CN119019320B (zh) * | 2024-10-29 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种具有抗血小板活性的哌啶类化合物的制备方法 |
| CN119192061B (zh) * | 2024-11-28 | 2025-05-13 | 上海柯君医药科技有限公司 | 一种含哌啶环的化合物的纯化方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2740686B1 (fr) | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
| FR2782455B3 (fr) | 1998-08-20 | 2000-09-15 | Sanofi Sa | Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine |
| JP5681485B2 (ja) * | 2007-04-27 | 2015-03-11 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法 |
| CN101579337A (zh) * | 2009-02-25 | 2009-11-18 | 牛华英 | 氯吡格雷组合物及其制备方法 |
| CA2761455C (en) * | 2009-05-13 | 2018-06-12 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| WO2014118649A2 (en) * | 2013-01-19 | 2014-08-07 | Mahesh Kandula | Compositions and methods for the treatment of cardiovascular diseases |
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554368A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN111848497A (zh) * | 2020-07-28 | 2020-10-30 | 内蒙古医科大学 | 氯吡格雷活性代谢物衍生物、其前药及其制备方法与应用 |
| AU2021317436A1 (en) * | 2020-07-29 | 2023-02-23 | Shanghai Curegene Pharmaceutical Co., Ltd. | Antiplatelet drugs and uses thereof |
-
2023
- 2023-01-16 TW TW112101736A patent/TW202339745A/zh unknown
- 2023-01-30 CA CA3248916A patent/CA3248916A1/en active Pending
- 2023-01-30 CN CN202380018894.4A patent/CN118613262A/zh active Pending
- 2023-01-30 JP JP2024544646A patent/JP2025508331A/ja active Pending
- 2023-01-30 AU AU2023211946A patent/AU2023211946A1/en active Pending
- 2023-01-30 WO PCT/IB2023/050766 patent/WO2023144782A1/zh not_active Ceased
- 2023-01-30 US US18/832,936 patent/US20250152571A1/en active Pending
- 2023-01-30 EP EP23746577.8A patent/EP4470539A4/en active Pending
- 2023-01-30 IL IL314332A patent/IL314332A/en unknown
- 2023-01-30 KR KR1020247028639A patent/KR20240142492A/ko active Pending
-
2025
- 2025-06-20 US US19/243,756 patent/US20250312326A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023211946A1 (en) | 2024-08-08 |
| JP2025508331A (ja) | 2025-03-26 |
| US20250152571A1 (en) | 2025-05-15 |
| EP4470539A1 (en) | 2024-12-04 |
| EP4470539A4 (en) | 2026-01-07 |
| KR20240142492A (ko) | 2024-09-30 |
| CN118613262A (zh) | 2024-09-06 |
| IL314332A (en) | 2024-09-01 |
| TW202339745A (zh) | 2023-10-16 |
| US20250312326A1 (en) | 2025-10-09 |
| WO2023144782A1 (zh) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4470539A1 (en) | Pharmaceutical composition of antiplatelet drug, and use thereof | |
| US12410132B2 (en) | Antiplatelet drugs and uses thereof | |
| EP3849984B1 (en) | 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof | |
| JP5875863B2 (ja) | マレイン酸オルブピタントの無水結晶形 | |
| US20230295166A1 (en) | Atr inhibitors and uses thereof | |
| WO2019109415A1 (zh) | 一种靶向降解hmgcr的化合物及其应用 | |
| US11834413B2 (en) | Antiplatelet drugs and uses thereof | |
| RU2841656C1 (ru) | Антитромбоцитарные лекарственные средства и их применение | |
| CN106045967B (zh) | 取代杂环化合物及其在药物上的应用 | |
| CN106045966B (zh) | 取代杂环化合物及其在药物上的应用 | |
| HK40090099A (zh) | 抗血小板药物和其用途 | |
| HK40117914B (zh) | 抗血小板药物和其用途 | |
| HK40117914A (zh) | 抗血小板药物和其用途 | |
| WO2023138621A1 (en) | Atr inhibitors and uses thereof | |
| EA051763B1 (ru) | Конденсированное пиридоновое соединение, способ его получения и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240716 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241219 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241219 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241219 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250117 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250207 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250207 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250908 |